Popular Articles

Sciele Pharma Announces Availability Of Ulesfia (Benzyl Alcohol Lotion 5%), First Prescription Non-Neurotoxic Head Lice Treatment
Sciele Pharma, Inc., a Shionogi Company, announced the availability of Ulesfia (Benzyl Alcohol Lotion 5%), the first and only prescription medication that kills head lice by asphyxiation without potential neurotoxic side effects. Approved by the U.S. Food & Drug Administration (FDA), Ulesfia is indicated for the topical treatment of head lice infestation in patients 6 months of age and older. Ulesfia is available now by prescription nationwide in time for peak head lice season.

NMC Statement Re Gosport War Memorial Hospital
The Nursing & Midwifery Council (NMC) is extremely concerned about the length of time that it is taking to resolve the issues for the families of former patients at Gosport War Memorial Hospital.
News of the day
Turner Syndrome Society Of The United States Announces Ambitious Goal To Crush Ignorance Of Turner Syndrome (TS)
The Turner Syndrome Society of the United States (TSSUS) recently concluded its 22nd Annual Conference in Portland, Oregon. The conference drew more than 350 individuals, families, researchers and health care professionals to network and learn about the latest research breakthroughs benefiting women and girls with TS.
Sexual Health

Study Links Recurrence Of Abnormal Cervical Cells To Age, Treatment Type

Older women, women with a higher grade of precancerous cells and women who undergo a freezing procedure known as cryotherapy to remove abnormal cervical cells are at a higher risk than other groups that the problem cells will return or develop into cervical cancer, according to a study published in the Journal of the National Cancer Institute, Reuters reports. For the study, Joy Melnikow of the University of California-Davis and colleagues compared 37,000 women who were treated for cervical intraepithelial neoplasia -- abnormal cervical cells -- from 1986 through 2000 with 71,000 women who had no history of abnormal cervical cells.The researchers found that the risk of cervical cancer and recurrence of medium to severe degrees of CIN was highest for women who were older than age 40, who had been previously treated for severe CIN or whose abnormal cells were treated using cryotherapy. The women underwent cone biopsies a surgical procedure to remove abnormal cells were least likely to have a recurrence of CIN. According to Melnikow, recurrence was most likely to occur within the first six years after treatment. Melnikow said that women who have been treated surgically have higher risks of bleeding and preterm labor. Therefore, younger women who are planning to become pregnant might prefer cryotherapy, she said, adding that younger women"s "risk of recurrence is lower, and a recurrence can be treated again" (Steenhuysen, Reuters, 5/12). Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women"s Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women"s Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company. © 2009 The Advisory Board Company. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):